| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 7.2% | $28.9M | 20.3M | T. Rowe Price Investment Management, Inc. | Jun 30, 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 5.3% | -33.8% | $21.4M | -$10.7M | 15M | -33.4% | Frazier Life Sciences Public Fund, L.P. | Jun 30, 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5.1% | +17.5% | $20.6M | $3.11M | 14.5M | +17.8% | Suvretta Capital Management, LLC | Jun 30, 2025 |
| Logos Global Management LP | 4.8% | -10% | $29.6M | -$3.27M | 13.6M | -9.93% | Logos Global Management LP | Sep 30, 2025 |
| NOVARTIS PHARMA AG | 4.4% | $17.1M | 12.3M | Novartis Pharma AG | Dec 31, 2024 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 215M | $469M | -$3.52M | $2.18 | 139 |
| 2025 Q2 | 218M | $277M | -$8.2M | $1.27 | 141 |
| 2025 Q1 | 224M | $307M | -$9.73M | $1.37 | 151 |
| 2024 Q4 | 231M | $579M | -$3.89M | $2.51 | 144 |
| 2024 Q3 | 232M | $633M | +$46.9M | $2.73 | 130 |
| 2024 Q2 | 204M | $480M | +$312M | $2.36 | 124 |
| 2024 Q1 | 72.7M | $150M | +$6.87M | $2.06 | 105 |
| 2023 Q4 | 69.2M | $148M | -$3.99M | $2.13 | 115 |
| 2023 Q3 | 71.3M | $140M | -$6.33M | $1.97 | 106 |
| 2023 Q2 | 74.3M | $205M | -$10.9M | $2.76 | 109 |
| 2023 Q1 | 78M | $235M | -$11.5M | $3.01 | 114 |
| 2022 Q4 | 79.8M | $344M | +$2.8M | $4.31 | 104 |
| 2022 Q3 | 80.5M | $628M | +$33.8M | $7.80 | 85 |
| 2022 Q2 | 76.9M | $428M | +$22M | $5.57 | 86 |
| 2022 Q1 | 72.8M | $626M | +$45.2M | $8.60 | 79 |
| 2021 Q4 | 63.7M | $988M | +$64.7M | $15.58 | 63 |
| 2021 Q3 | 44.1M | $919M | +$919M | $21.22 | 53 |